Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 7

Comparison of adverse events between our study and previous clinical studies of intrathecal allogeneic MSCs.

Adverse events (person-time)	Total (%)	Our study (%)	Literature review (%)
Headache	10 (2.48)	3 (2.05)	7 (2.71)	0.940
Dizziness	8 (1.98)	2 (1.37)	6 (2.33)	0.771
Fever	8 (1.98)	5 (3.42)	3 (1.16)	0.232
Nausea	2 (0.50)	2 (1.37)	0 (0.00)	0.130
Pain at puncture site	7 (1.73)	6 (4.11)	1 (0.39)	0.018
Neck pain	1 (0.25)	1 (0.68)	0 (0.00)	0.361